tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Optimistic Buy Rating for Celldex Driven by Promising Clinical Developments and Strong Financial Position
PremiumRatingsOptimistic Buy Rating for Celldex Driven by Promising Clinical Developments and Strong Financial Position
18d ago
Celldex reports Q3 EPS ($1.01), consensus (89c)
Premium
The Fly
Celldex reports Q3 EPS ($1.01), consensus (89c)
19d ago
Celldex appoints Lawver as Chief Commercial Officer
Premium
The Fly
Celldex appoints Lawver as Chief Commercial Officer
19d ago
Celldex presents results from Barzolvolimab Phase 2 Study in ColdU, SD
PremiumThe FlyCelldex presents results from Barzolvolimab Phase 2 Study in ColdU, SD
23d ago
CLDX Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
CLDX Upcoming Earnings Report: What to Expect?
26d ago
Celldex’s Promising Clinical Data and Strategic Development Plans Drive Buy Rating
Premium
Ratings
Celldex’s Promising Clinical Data and Strategic Development Plans Drive Buy Rating
29d ago
Celldex’s barzo shows strong efficacy in CSU patients, says H.C. Wainwright
PremiumThe FlyCelldex’s barzo shows strong efficacy in CSU patients, says H.C. Wainwright
2M ago
Celldex’s Barzolvolimab Shows Promising Efficacy in Treating Chronic Spontaneous Urticaria Across Patient Subgroups
Premium
Ratings
Celldex’s Barzolvolimab Shows Promising Efficacy in Treating Chronic Spontaneous Urticaria Across Patient Subgroups
2M ago
Celldex announces new barzolvolimab data at EADV congress
Premium
The Fly
Celldex announces new barzolvolimab data at EADV congress
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100